BioSpace News Archive

OPKO Health, Inc. reports business highlights and financial results for the three and six months ended June 30, 2022.

Gritstone bio, Inc., a clinical-stage biotechnology company working to develop the world’s most potent vaccines, reported financial results for the second quarter ended June 30, 2022 and reviewed business highlights.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, reported financial results for the three and six months ended June 30, 2022.

Calyxt, Inc., a plant-based synthetic biology company, announced financial results for its second quarter ended June 30, 2022.

Evofem Biosciences, Inc., reported financial results for the three- and six-month periods ended June 30, 2022 and affirmed full-year 2022 guidance.

Ardelyx, Inc. (Nasdaq: ARDX), today reported business updates and financial results for the second quarter ended June 30, 2022.

Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced initial findings from an investigator-sponsored study evaluating vadadustat, Akebia’s investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for the prevention and treatment of ARDS in clinical trial subjects with COVID-19 and hypoxemia.

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ending June 30, 2022.

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus infection and other serious diseases, reported financial results for second quarter 2022 and provided a business update.

Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three- and six-month periods ended June 30, 2022.